Angion Biomedica

Angion Biomedica Corp. operates as a biopharmaceutical company. The firm focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 06, 1998 and is headquartered in Uniondale, NY.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. It focuses on its Amphiphile platform for trafficking lymph nodes. The company was founded by Darrell Irvine in August 2011 and is headquartered in Boston, MA.

Ended the quarter with nearly $103M in cash and cash equivalents Ended the quarter with nearly $103M in cash and cash equivalents

Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results

UNIONDALE, N.Y., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases presented four posters at the American Society of Nephrology's Kidney Week 2021 virtual meeting, which is being held from November 4 to 7, 2021.

Angion Presents Multiple Posters on ANG-3070 at Kidney Week 2021, Including Preclinical Data and Design of Upcoming Phase 2 Study

UNIONDALE, N.Y., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced its management team will participate in a fireside chat with Stifel Managing Director and Senior Analyst Annabel Samimy at the Stifel 2021 Virtual Healthcare Conference.

Angion to Participate in Upcoming Investment Conference

After flopping a test in COVID-19 earlier this year, Angion Biomedica Corp's (NASDAQ: ANGN) lead candidate drug has hit a setback again, this time in kidney transplant patients. Related:   Angion Stock Falls As Lead Product Candidate Flunks In COVID-19 Trial

Why Did Angion Biomedica's Shares tumble Premarket Today?

ST. GALLEN, Switzerland & UNIONDALE, NY--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced that the phase-III trial of Angion's ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing DGF. ANG-3777 showed a modest but not statistically s

Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function

Angion to host a conference call at 4:30 p.m. EDT Angion to host a conference call at 4:30 p.m. EDT

Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk for Delayed Graft Function

UNIONDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced it will be presenting four posters at the American Society of Nephrology's Kidney Week 2021 virtual meeting to be held November 4-7, 2021.

Angion to Present Multiple Posters at Kidney Week 2021

UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, announced today it is scheduled to host a virtual research and development day focused on its product candidate ANG-3070, a novel, highly selective, and orally-bioavailable small molecule tyrosine kinase receptor inhibitor in clinical development for the treatment of fibrotic diseases, including those in the kidney and lung, at 10:00am EDT on Monday, September 20th.

Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis

UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced its management team will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference and participate in a fireside chat with Oppenheimer Senior Biotech Analyst Justin Kim at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

Angion to Participate in Upcoming September Investment Conferences

Angion Biomedica Corp (NASDAQ: ANGN) has announced positive results from its Phase 1 study in healthy volunteers for ANG-3070 for fibrotic diseases.  In the 97-volunteer trial, ANG-3070 achieved drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney diseases.

Angion Biomedica Shares Moving Higher On Encouraging Results From Early Stage Trial Of Fibrotic Disease Candidate

UNIONDALE, N.Y., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced positive results from its Phase 1 study in healthy volunteers for ANG-3070, a novel oral tyrosine kinase receptor inhibitor (TKI) being developed for the treatment of fibrotic diseases. Angion also announced the FDA's acceptance of an IND application supporting the initiation of a Phase 2 trial in patients with primary proteinuric kidney diseases in 2021. Additionally, the Company announced it will host a Virtual Fibrosis R&D Day on September 20, 2021.

Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021

UNIONDALE, N.Y., June 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced that its exploratory Phase 2 ALI-201 trial of ANG-3777 in patients with severe COVID-19 related pneumonia at high risk for acute respiratory distress syndrome (ARDS) did not meet the primary or secondary efficacy endpoints. The adverse events and overall safety of the trial were consistent with previously published reports in patients hospitalized with severe COVID-19 pneumonia.

Angion Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia

UNIONDALE, N.Y., May 17, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provided a corporate update and reported financial results for the quarter ended March 31, 2021.

Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results

ST. GALLEN, Switzerland & UNIONDALE, NY--(BUSINESS WIRE)--Regulatory News: Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of enrollment for Angion's AKI-002-15 study, a phase-II trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI). This indication is part of the ANG-3777 license agreement both parties signed in November 2020. “CSA-AKI is a frequent complication of cardiac bypass surgery seen in about one third of p

Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury

Topline data expected in the second half of 2021 Topline data expected in the second half of 2021

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Angion is a recent IPO. It has an ongoing phase 3 trial with near-term data readout.

Angion Biomedica: Interesting New IPO With Late Stage Asset Targeting A Novel Indication

UNIONDALE, N.Y., March 30, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2020.

Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Topline data expected in the first half of 2021 Topline data expected in the first half of 2021

Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated Pneumonia

UNIONDALE, N.Y., March 19, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated, the lead book-running managers in Angion's recent public sale of 5,750,000 shares of common stock, have agreed to a partial wavier of a lock-up restriction with respect to approximately 100,267 shares of Angion's common stock held by certain employees or officers of the company. The shares will be sold solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock or Restricted Stock Unit awards held by such employees pursuant to Angion's employee equity incentive plans. The waiver will take effect on March 23, 2021, and the shares may be sold on or after such date.

Angion Announces Partial Waiver of Certain Lock-up Restrictions

The stock price of Angion Biomedica Corp (NASDAQ: ANGN) is trading at over 25% pre-market. This is why it happened.

ANGN Stock Price Increases Over 25% Pre-Market: Why It Happened

UNIONDALE, N.Y., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced its management team will present at the H.C. Wainwright Global Life Sciences Conference and the Oppenheimer 31st Annual Healthcare Conference. Dr. Jay Venkatesan, Angion's President and CEO, will also participate in a panel focused on kidney diseases at the Cowen 41st Annual Health Care Conference. All three virtual investor conferences will take place in March 2021.

Angion to Participate in Upcoming March Investment Conferences

UNIONDALE, N.Y., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the closing of $117 million in gross proceeds from its previously announced initial public offering and concurrent private placement.

Angion Biomedica Corp. Announces Closing of $117 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Atotech

Bolt Biotherapeutics

Immunocore Holdings

Landos Biopharma

Lucira Health

ON24

Pharvaris B.V.

Sana Biotechnology

Sensei Biotherapeutics

Terns Pharmaceuticals

TELUS International (Cda)

Vor Biopharma

The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. German chemicals group Atotech downsized and priced below the range to raise $498 million at a $3.3 billion market cap.

U.S. IPO Weekly Recap: Biotechs Flood The IPO Market In A 14 IPO Week

A flock of biotech companies are opening for trading Friday. Most of the deals grew in size, with price increases as well.

The Biotech IPO Wave Continues. Here Are 7 Stocks Hitting the Market.

UNIONDALE, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the pricing of its initial public offering on February 4, 2021 of 5,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $80,000,000 million, before deducting the underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Angion. Angion has also granted the underwriters a 30-day option to purchase from Angion up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Angion's common stock has been approved for listing on The Nasdaq Global Select Market and is expected to begin trading under the ticker symbol “ANGN” on February 5, 2021. The offering is expected to close on February 9, 2021, subject to satisfaction of customary closing conditions.

News for Angion Biomedica Stock (ANGN)